Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry. (Q54628554)

1 June 2018

title

Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry. (English)

1 reference

1 June 2018

author

Giuseppe Giaccone

6

1 reference

1 June 2018

author name string

T Harada

1

1 reference

1 June 2018

A Lopez-Chavez

2

1 reference

1 June 2018

L Xi

3

1 reference

1 June 2018

M Raffeld

4

1 reference

1 June 2018

Y Wang

5

1 reference

1 June 2018

language of work or name

English

0 references

publication date

6 December 2010

1 reference

1 June 2018

published in

Oncogene

1 reference

1 June 2018

volume

30

1 reference

1 June 2018

issue

15

1 reference

1 June 2018

page(s)

1744-1752

1 reference

1 June 2018

describes a project that uses

ImageJ

1 reference

11 June 2022

https://www.ebi.ac.uk/europepmc/webservices/rest/PMC7213757/fullTextXML

based on heuristic

inferred from PubMed Central ID database lookup

exact match

https://scigraph.springernature.com/pub.10.1038/onc.2010.545

0 references

cites work

Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.545

Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.545

Functional analysis of cancer-associated EGFR mutants using a cellular assay with YFP-tagged EGFR intracellular domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.545

PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.545

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.545

Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.545

Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.545

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.545

Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.545

Ethnic differences and functional analysis of MET mutations in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.545

Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.545

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.545

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.545

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.545

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.545

Screening for epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.545

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.545

Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.545

HKI-272 in non small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.545

Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.545

Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.545

Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.545

An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.545

The EGF Receptor Hokey-Cokey

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.545

21 January 2018

Identifiers

DOI

10.1038/ONC.2010.545

1 reference

1 June 2018

0 references

1 reference

1 June 2018